Respiratory training for patients with Friedreich's Ataxia
Official title: Impact of Respiratory Training in Swallowing and Respiratory Function in Patients With Friedreich's Ataxia
Run by University of Florida · NCT06539598 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing if a 12-week breathing exercise program can help improve lung function and quality of life for people with Friedreich's Ataxia.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 8 (estimated) |
| Sponsor | University of Florida Academic / other |
| Locations | 1 site (Gainesville, Florida) |
| Trial ID | NCT06539598 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals with confirmed genetic testing for Friedreich's Ataxia who can perform pulmonary function testing.
✕Probably not a fit
Patients with recent antibiotic use, systemic corticosteroid prescriptions, or other significant medical conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study focuses on patients diagnosed with Friedreich's Ataxia who will undergo a 12-week program of respiratory strength training. Participants will have two research visits, one at the beginning and one at the end of the training period, during which they will undergo various evaluations including swallowing assessments, pulmonary function tests, and surface electromyography. The aim is to assess the impact of respiratory training on their overall respiratory function and quality of life.
Why it matters
Potential benefit: If successful, this study could improve respiratory function and quality of life for patients with Friedreich's Ataxia.
How similar studies have gone: While there may be limited studies specifically on respiratory training in Friedreich's Ataxia, similar approaches in other neuromuscular conditions have shown promise.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * confirmed genetic testing of Friedreich's Ataxia * have an overall DIGEST score of 1 or higher based on FEES screening * are able to perform pulmonary function testing Exclusion Criteria: * have been on antibiotics within 15 days prior to baseline screening. * have been prescribed systemic corticosteroids or neuromuscular blocking agents within 15 days of the baseline screening * have an allergy or contraindication to topical lidocaine or oxymetazoline * have any other concurrent medical condition which, in the opinion of the investigators, would make the subject inappropriate to participate in testing or respiratory exercise
Where it's running
-
Clinical Research Center
Gainesville, Florida, United States Recruiting
Study contacts
- Principal investigator: Carmen Leon Astudillo, MD — University of Florida
- Study coordinator: Mackenzi Coker, MS, CCC-SLP
- Email: mcoker@peds.ufl.edu
- Phone: 3522948754
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Nomlabofusp by injection for Friedreich's Ataxia: efficacy and safety
This study tests whether subcutaneous nomlabofusp helps adults and children with Friedreich's Ataxia compared with placebo.
-
LX2006 Gene Therapy for Friedreich Ataxia Cardiomyopathy (FA-CM)
A Phase 2 study tests LX2006 gene therapy in people with Friedreich ataxia who also have cardiomyopathy to see if it helps heart function and safety.
-
Nerve ultrasound in people with Friedreich ataxia
This project uses routine peripheral nerve ultrasound to see if adults with genetically confirmed Friedreich ataxia have enlarged nerves.
-
Omaveloxolone for swallowing problems in French people with Friedreich's ataxia
This project will test whether omaveloxolone (SKYCLARYS) improves swallowing in French people aged 16 and older with genetically confirmed Friedreich's ataxia who have used the drug for at least six months.
-
Testing DT-216P2 in patients with Friedreich's Ataxia
This study is testing a new drug called DT-216P2 in adults with Friedreich's Ataxia to see how safe it is and how well it works in their bodies.
-
Clinical course of cardiomyopathy in people with Friedreich ataxia
This study follows people with Friedreich ataxia who have cardiomyopathy to see how their heart disease changes over time and to identify who may later be eligible for a gene therapy study.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.